BMS takes on 'new normal' as it gears up for Eliquis launch
This article was originally published in Scrip
Executive Summary
2012 was a year of transition for Bristol-Myers Squibb, which saw it turn the patent cliff into a "much reduced patent slope", according to CEO Lamberto Andreotti, who was speaking at the JP Morgan global healthcare conference on 8 January.